Kornimate/medical-research-clean huggingface dataset:
edaravone on the ischemia-reperfusion(i/r) injury in kidney transplantation patients

Conditions: Kidney Transplantation

Summary: ischemia-reperfusion (i/r) injury is a prominent cause of delayed graft function(dgf) after kidney transplantation. reactive oxygen species play a crucial role in i/r injury. edaravone is a synthetic radical scavenger that has been used in acute stroke. some animal experiments have revealed its beneficial effects against i/r injury, our goal is therefore to investigate the effectiveness of a recipient pretreatment with edaravone at reducing the occurrence of dgf after kidney transplantation.

participants will be randomly assigned, in a 1:1 ratio, to receive edaravone or control (0.9 %sodium chloride solution,0.9%nacl). the randomization sequence will be computer-generated, and randomization will be performed in blocks and will be stratified according to participating center.edaravone and 0.9 %nacl solution will be treated at 10 minutes before kidney reperfusion, ending in 30 minutes. the number of dialysis and the serum creatinine level within the first week after the transplantation will be recorded. the participation of each patient is scheduled for 1 month.

Eligibility criteria:
inclusion criteria: 1. asaⅱ-ⅲ,elective operation patients with end-stage renal disease 2. age 18yrs-55yrs for donors and the recipients 3. patients under hemodialysis 4. no other severe complications history for the donors and recipients 5. the first kidney transplant recipients 6. patients with written informed consent exclusion criteria: 1. asa ⅳ 2. a second renal transplant,a multiorgan transplant or a dual kidney transplant 3. having severe comorbidity history,for example,severe cardiac dysfunction 4. cold ischemia time\>24h or warm ischemia time\>45min 5. variation of blood vessel ，operation time more than 2 hours 6. bleeding volume in operation\>500ml and need for blood transfusion 7. participate in the other clinical trial 3 months before the enrollment 8. no suitable to participate in this experiment

Keywords: ischemia-reperfusion(i/r) injury edaravone
usage of tramadol with levobupivacaine for pain treatment after cesarean section

Conditions: Pain, Postoperative

Summary: patients experience considerable amount of pain after cesarean section. the aim of this study is to investigate the effect of tramadol (an opioid pain killer) added to levobupivacaine (a local anesthetic) in continuous wound infusion (which is done by placing a catheter in the incision) after cesarean sections.


Eligibility criteria:
inclusion criteria: * planned cesarean section * american society of anesthesiologists class i-ii exclusion criteria: * patients refusing to enroll in the study * serious coagulopathy * serious systemic disease * story of allergy to drugs being used in the study * morbid obesity (body mass index \> 30)
exploring biological linkage between circadian disruption and cancer progression

Conditions: Breast Neoplasms

Summary: the purpose of this study is to explore the possible association between the circadian disruption and cancer progression.

the biological markers that are assumed to bridge this association are measured and analyzed.

Eligibility criteria:
inclusion criteria: * age: 18-70 * breast cancer patients who are getting chemotherapy for the first time in life * patients are either having stage 4 cancer or starting neoadjuvant chemotherapy. * patient have signed on the informed consent, and well understood the objective and procedure of this study exclusion criteria: * patients already have received chemotherapy * patient had another cancer (except thyroid cancer) within 5 years * patient with severe medical condition * patient had taken psychiatric medication more than 1 month in life * patient worked the night shift for more than 1 month in 6 months

Keywords: breast neoplasms circadian rhythm sleep survival distress anxiety depression quality of life actigraph fatigue
clinical evaluation of laterally closed tunnel technique versus coronally advanced flap combined with connective tissue graft for the treatment of isolated rt2 gingival recession

Conditions: Recession, Gingival

Summary: the aim of this study is to evaluate reduction of recession depth using lateral closed tunnel technique versus caf technique using connective tissue graft in single rt2 gingival recession cases.


Eligibility criteria:
inclusion criteria: * single rt2 buccal gingival recession ≥ 2 mm in the esthetic zone (gingival recession associated with loss of inter-proximal attachment. the amount of interproximal attachment loss (measured from the interproximal cej to the depth of the interproximal pocket) was less than or equal to the buccal attachment loss (measured from the buccal cej to the depth of the buccal pocket) * patients with good oral hygiene * medically free patients * no signs of active periodontal disease (with no site showing probing depth \> 4 mm and full-mouth bleeding score (fmbs) 20% (measured at four sites per tooth). * palate with sufficient thickness to accommodate soft tissue defect. exclusion criteria: * smokers * pregnancy * severe gag reflex * non-carious cervical lesion * history of mucogingival or periodontal surgery at the experimental site * history of medication that can affect periodontal healing
tbi evaluation and management (team)

Conditions: Mild Traumatic Brain Injury

Summary: the purpose of this study is to evaluate a multi-disciplinary, multi-setting intervention with the goal of improving outcomes for children who have experienced a mild traumatic brain injury (mtbi). the project aims to improve and support mtbi diagnosis and management, and improve critical decision making by clinicians during their interaction with the injured child, their family, and their school.

emergency, urgent care, and primary care providers participating in the study will be block randomized in a 1:1 ratio by practice type to receive the intervention or continue with their standard practice. all enrolled clinicians (both trained and control providers) patients they care for will be screened for inclusion in the trial. additionally, a pre/post intervention will be layered upon the randomized educational intervention to evaluate the effects of the information technology decision support tool (i.e. emr) in isolation of the clinician education intervention. the 32-month mtbi patient enrollment period will be divided into two 16 months segments. the first 16 months will be without the emr intervention being visible, and the remaining 16 months post emr screening and decision support deployment in the ed and uc. this study design allows us to evaluate the independent and interactive effects of the decision support tool and educational intervention. enrolled children will be followed for up to three months post injury to ascertain the effect of the interventions on the primary aim (reduction of school problems/performance) and secondary aims.

Eligibility criteria:
provider inclusion criteria * actively practicing physician or app in the choa system * primary practice in either ed, uc, and/or pcp provider exclusion criteria * inability or unwillingness to provide written/electronic informed consent * unable to fulfill study training / education requirements child inclusion criteria - retrospective * school age (5-18 yoa) * evaluated in ed / uc / pcp within 72 hours of injury * discharged home from ed / uc / pcp (e.g., not admitted to hospital) child exclusion criteria - retrospective * non-english speaking * known severe developmental delay or known severe psychiatric history * known prior severe brain injury * known mtbi within past 3 months * first mtbi visit outside of choa network child inclusion criteria - prospective * meets above inclusion for retrospective portion plus: * mtbi likely present as defined by: * positive diagnosis by clinician or mtbi or * positive triage screen plus positive symptom checklist child exclusion criteria - prospective * does not meet above exclusion for retrospective portion plus: * requests to opt-out via e-mail or first phone contact * inability or unwillingness to provide verbal informed telephone consent/assent

Keywords: mtbi brain injury emergency medicine urgent care primary care concussion pediatrics
randomized evaluation of the effectiveness of clozapine and aripiprazole versus clozapine and haloperidol in the treatment of schizophrenia

Conditions: Schizophrenia

Summary: the principal clinical question to be answered by chat (clozapine haloperidol aripiprazole trial) is the relative efficacy and tolerability of combination treatment with clozapine plus aripiprazole compared to combination treatment with clozapine plus haloperidol in patients with an incomplete response to treatment with clozapine over an appropriate period of time.


Eligibility criteria:
inclusion criteria: 1. current treatment with clozapine for the primary indication of schizophrenia (clinical diagnosis, guided by dsm-iv criteria). 2. treatment with clozapine for at least six months at a stable dose of 400 mg or more per day, unless the size of the dose was limited by side-effects. 3. unsatisfactory benefit from clozapine treatment, as indicated by the presence of positive symptoms (delusions, hallucinations, abnormal behaviour, clinical diagnosis) 4. age 18 and above. 5. agreement between investigator and patient to enter the study. 6. the patient is normally resident in italy. 7. it is considered clinically reasonable to try combination treatment with clozapine and aripiprazole or with clozapine and haloperidol. 8. uncertainty about which trial treatment would be best for the participant. 9. no medical disorder or condition contraindicates either of the investigational drugs. 10. agreement between investigator and patient to discontinue any antipsychotic drugs other than clozapine (including long-acting antipsychotic drugs).

Keywords: schizophrenia antipsychotics treatment non response pragmatic trial
exercise capacity of patients with dermatomyosis

Conditions: Dermatomyositis

Summary: dermatomyositis (dm) patients experience muscle weakness and low aerobic capacities, which are associated with poor health status and increased mortality. the origin of this muscle impairment remains unknown. the investigators hypothesize that mitochondria functioning is impaired in dm muscle and links with exercise capacities.


Eligibility criteria:
inclusion criteria: * woman or man\> 18 years, * signature of informed consent, * muscle biopsy for suspicion of recent inflammatory myopathy (\<6 months) or for exclusion of neuromuscular pathology. prospectively, following the results of the muscle biopsy, the subjects will divided into three groups meeting the following criteria: * "dm" group: dm according to the enmc criteria; * "other inflammatory myopathy" group: polymyositis, autoimmune necrotizing myopathy, non-specific myositis or inclusion myositis according to the enmc criteria; * group "no neuromuscular pathology": i) myalgia and / or intolerance to exercise and ii) normal neuromuscular examination, iii) no increase in blood creatine kinase level, iv) absence of electromyographic abnormality, v) histological muscle mass. exclusion criteria: * - taking an immunomodulatory treatment within 6 months before inclusion, * paraneoplastic form of the disease, * presence of associated interstitial pneumonitis, * neuromuscular pathology different from inflammatory myopathy, * unbalanced cardiovascular disease, * impossibility of giving the subject informed information (subject in an emergency situation, difficulty in understanding the subject, ...), * subject under safeguard of justice, * subject under tutelage or under curators, * pregnancy (positive pregnancy test) * breastfeeding.
investigating the role of brain-derived neurotrophic factor (bdnf) between pain and other neuronal disease

Conditions: Pain

Summary: measure the cytokines, transforming or neurotrophic factors in csf and plasma as the pain markers and as a new therapeutic target for pain control.

the research protocol was approved by the institutional review board (irb) for the protection of human subjects at national cheng kung university hospital (nckuh/b-er-104-070). the study procedures were performed according to the rules of irb and fully explained to the participants. blood and csf samples were collected and compared the difference in no pain group, acute pain group, and chronic pain group.

Eligibility criteria:
inclusion criteria: * . patients undergo spinal anesthesia * . over 20 years of age * patients who are competent to understand the study and provide written informed consent. exclusion criteria: * patients have the contraindication for spinal anesthesia (refuse spinal anesthesia, coagulopathy, severe aortic stenosis) * refuse participated in this study or pre-existent neurological disease. * patients with advanced tumor staging (stage 3 or 4).

Keywords: pain
study of the environmental factors modulating children immune response in northern senegal

Conditions: Whooping Cough; Malaria; Malnutrition

Summary: longitudinal survey in northern senegal to investigate the environmental factors modulating the immune response to childhood vaccines and to malaria. a cohort of 410 children aged 1 to 10 from 5 villages of the senegal river valley(podor district) was followed-up for 18 months. during that period, 5 visits have been made to the villages to assess the immunological and nutritional status of the children.

longitudinal survey in northern senegal to investigate the environmental factors modulating the immune response to childhood vaccines and to malaria. a cohort of 410 children aged 1 to 10 from 5 villages of the senegal river valley(podor district) was followed-up for 18 months. during that period, 5 visits have been made to the villages to assess the immunological and nutritional status of the children (t1 (october 2008), t2 (january 2009), t3 (june 2009), t4 (october 2009) and t5 (january 2010)). the project was approved by the national ethics committee of senegal. written individual informed consent was obtained from each participant's parent or legal guardian at the beginning of the survey, and at each visit child's and parent's approval was sought orally. capillary blood was collected from the finger tip of each child, using sterile single-use material. body temperature was measured by means of auricular thermometer at all visits. anthropomorphic data were collected at visits t2, t3, t4 and t5. a hemocue photometer (hemocue ab, ängelholm, sweden) was used to determine haemoglobin concentration on a blood drop at visits t3, t4 and t5. at each visit, a questionnaire was filled in for every child. information was collected on the date of birth family membership to asses if siblings or children living in the same house were in the cohort.

Eligibility criteria:
inclusion criteria: * age: between 1 and 10 years exclusion criteria: * fever (body temperature superior to 38.5 °c)

Keywords: children immunity sub-saharan pertussis malaria nutrition antibodies
liquorice and salivary cortisol

Conditions: Cushing Syndrome; Hypercortisolism

Summary: salivary cortisol is used as a diagnostic analysis in the investigation of suspected cushings' syndrome. this study evaluates if liqourice intake increases salivary cortisol in healthy individuals. late night salivary cortisol and cortisone is analysed before, during and after 7 days of liqourice intake in three different doses.


Eligibility criteria:
inclusion criteria: * men and women 18-65 years. exclusion criteria: * known pituitary or adrenal disease * medication with glucocorticoids (incl. inhalation, nasal, dermal) * known hypertension or blood pressure \>140/90 at screening * tobacco use * subjective problems in oral mucosa or saliva * abnormal diurnal rhythm (awake 03:00 - 05:30) * difficulties taking liqourice for 3 weeks or refraining from liqourice during 4 weeks
concurrent training and nutritional management in cancer

Conditions: Body Weight Changes

Summary: a case control study with before-after design. a concurrent training and a nutritional management intervention was offered by a patient with head and neck cancer, in order to compare outcomes related to strength and endurance performance and to body composition

cancer causes important public health problems around the world and it is one of the most frequent cause of death overall. among non-pharmacological treatment, physical exercise has shown improvements in different types of cancer and patients, but it is important to define the optimal dose. our aim is to determine the effects of a concurrent training program and a nutritional management developed during radiotherapy treatment on physical performance and body composition. a patient with an oral cavity cancer will develop three sessions per week of concurrent training: resistance training included 9 standard exercises involving major muscle groups (4x8-12 rm), and cardiovascular training included a high-intensity interval training (hiit). nutritional management will include a diet controlling macronutrients (\~4g/kg/day for carbohidrates, \~2g/kg/day for proteins, and \~1g/kg/day for fats), along with some nutritional supplements such as beta-hydroxybeta-methylbutyrate (hmb), arginine, glutamine, omega-3 fish oil concentrate, and bcaa's during training sessions. intervention took place during radiotherapy period (7 weeks). we expect that body composition will remain invariable, and 1rm will increased. vo2max is expected to be almost the same, but intensity tolerated at maximum vo2max could be higher. if our results confirm that, we could conclude that a combination between resistance exercise and hiit along with a nutritional management developed during radiotherapy could be effective to prevent muscle mass loss and muscle function decrease in a young patient with oral cavity cancer.

Eligibility criteria:
this is a case control study
study with vortioxetine on emotional functioning in patients with depression

Conditions: Major Depressive Disorder

Summary: the study will evaluate effectiveness of flexible dose vortioxetine 10-20 mg/day on emotional functioning in patients with mdd with an inadequate response to ssris/snris.


Eligibility criteria:
inclusion criteria: * the patient has a primary diagnosis of single or recurrent mdd according to dsm-5®. the current major depressive episode (mde) must be confirmed using the mini international neuropsychiatric interview (mini). * the patient has had the current mde for \<12 months. * the patient has a montgomery and åsberg depression rating scale (madrs) total score ≥ 22 and ≤ 28 at the baseline visit. * the patient has been treated with ssri/snri monotherapy (citalopram, escitalopram, paroxetine, duloxetine or venlafaxine) for at least 6 weeks at adequate dose for the current mde and with an inadequate response and is a candidate for a switch in the investigator's opinion. * the patient wants to switch antidepressant treatment. * the patient has an odq total score ≥50 at baseline, while on ssri/snri monotherapy (prior to switch). * the patient answered "yes "to the screening question on emotional effects. exclusion criteria: - the patient has a significant risk of suicide according to the investigator's clinical judgment or has made an actual suicide attempt in the previous 6 months prior to baseline other in- and exclusion criteria may apply
achieving hybrid monovision by paring monofocal and edof lens technology

Conditions: Cataract Senile

Summary: modern day cataract surgery isn't just a rehabilitative procedure anymore but rather aims at improving a patient's quality of life by reducing the need for spectacles in everyday life to a minimum. one way of achieving this goal is by using different lens technologies, such as a monofocal lens paired a lens with edof technology, as edof lenses provide an enhanced depth of focus by creating a single elongated focal point. as this "mix-and-match" is well established, the aim of this study is to compare the monofocal lens cohort to the edof lens cohort and evaluate visual acuity and patient satisfaction.


Eligibility criteria:
inclusion criteria: * patient age between 21-99 years * signed consent form * senile cataract locs iii grading * cataract surgery with monofocal or premium lens implantation exclusion criteria: * missing signed consent form * macular pathologies * corneal pathologies * irregular astigmatism * pregnancy
a specification clinical application research of tripterygium wilfordii treating rheumatoid arthritis

Conditions: Rheumatoid Arthritis

Summary: rheumatoid arthritis (ra) is an autoimmune disease that results in a chronic inflammatory disorder that may affect many synovial joints, and may cause serious disability. it has been confirmed that tripterygium wilfordii has effects of anti-inflammatory, immunosuppressive and cartilage protection. this is a multicenter ,double blind, randomized study to evaluated the efficacy and safety of tripterygium wilfordii in treating of patients with rheumatoid arthritis (ra) and establish a prediction model for tripterygium wilfordii response of rheumatoid arthritis (ra).

two arms were included in this study. active comparator: patients were treated with methotrexate (mtx)and tripterygium wilfordii hook f（twhf）placebo.experimental:patients were treated with methotrexate (mtx) placebo and tripterygium wilfordii hook f（twhf)

Eligibility criteria:
inclusion criteria: * diagnosed with rheumatoid arthritis as determined by the 1987 or 2010 acr classification criteria; * no male or female fertility requirements, or around menopause women; * patients with mild-to-moderate activity, 2.6 \< das28≤5.1; * no serious system involved, such as severe pericardial effusion, interstitial lung disease, renal tubular acidosis, atrophic gastritis, autoimmune liver disease, etc; * within a month before the selected participants did not attend any drugs exclusion criteria: * patients with cancer or other malignant disease such as cardiovascular, hematopoietic, liver and kidney disease, and psychopath * active or chronic infection, including hiv, hepatitis c virus, hepatitis b virus, tuberculosis * previous treated with tripterygii, glucocorticoid or biologic disease-modifying antirheumatic drug (dmard) in 3 months. * previous treated with tripterygium wilfordii or mtx * patients with retinopathy.